|
|
| |
| Cancer Mutations Are Showing Up in Brain Immune Cells—and They May Be Fueling Alzheimer’s |
| This one caught me off guard. Researchers at Mount Sinai and Boston Children’s Hospital found that the same genetic mutations that drive blood cancers are piling up inside your brain’s immune cells—the microglia. But they’re not causing cancer there. They’re doing something else. |
| Let me explain. Microglia are your brain’s cleanup crew. They patrol for damage, eat debris, and call for backup when something goes wrong. In a healthy brain, they do their job and stand down. But as you age, some of these cells pick up mutations—the same ones found in a blood condition called clonal hematopoiesis, where mutant blood cells start to crowd out normal ones. |
| The team used deep genetic sequencing and single-cell analysis to show what happens next. Those mutant microglia don’t just sit there. They shift into an aggressive, inflammatory state. They divide faster. They outcompete healthy microglia. And the chronic inflammation they produce damages nearby neurons—innocent bystanders caught in the crossfire. Think of it like a security guard who starts breaking things instead of protecting them. |
| |
The researchers believe the blood-brain barrier weakens with age, letting mutant blood cells slip into the brain and convert into microglia-like cells. Once inside, protein clumps like amyloid and tau create a hostile environment—and the mutant cells thrive in it. |
|
| I could be wrong, of course. This is still early work. But the possibility is striking: cancer drugs that target these exact mutations might one day be repurposed for Alzheimer’s. And because these mutations show up in blood cells too, a simple blood test could flag your risk long before symptoms appear. |
| I believe this is one of the most important Alzheimer’s findings this year. It changes how we think about the disease—not just as a protein problem, but as an immune system problem. Take a hard look at this one. |
| Mount Sinai · Boston Children’s Hospital · Cell · June 11, 2026 |
|
|
|
|
| |
| Pick Up an Instrument—Even Now |
| A four-year study from Kyoto University tracked people who started learning a musical instrument at an average age of 73. Half kept playing. Half quit after the initial training and did other hobbies instead. |
| Four years later, the difference was plain on brain scans. The people who quit showed measurable memory decline and actual shrinkage in the putamen—a brain region that handles motor learning and memory. The ones who kept playing? No decline. Their brains held steady. |
| You see, playing music does something special. It forces your brain to read, listen, move your hands, keep time, and remember sequences—all at once. No single activity hits that many brain systems simultaneously. And the data says the benefit stacks over time. So the key is not to stop. |
| The Protocol |
| When |
| Same time each day—morning or evening, whichever you’ll actually stick to |
| Duration |
| 15–20 minutes per session, daily |
| Rules |
| Pick one instrument—piano, ukulele, harmonica, anything with melody. Follow a structured lesson (app or teacher). The brain benefit comes from reading notation, coordinating hands, and keeping rhythm together. Don’t stop after the first few months. The Kyoto data is clear: people who quit lost the gains. |
| |
| Watch for frustration in the first two weeks—that’s normal and it fades. Your brain is building new wiring. I urge you to try it. |
|
|
|
|
|
|
|
| A Popular Focus Supplement May Shorten Men’s Lives |
| Tyrosine is sold in gyms and health stores as a focus and brain-performance booster. But a study of over 270,000 people found that men with higher blood levels of this amino acid lived roughly one year less than men with lower levels. The effect did not appear in women. The study measured naturally occurring tyrosine levels—not supplement use directly—so this is not a final verdict. But if you’re taking tyrosine pills for mental sharpness, it’s worth a pause. |
| Aging-US · June 15, 2026 |
|
|
| One Bag of Chips a Day Is Enough to Dull Your Focus |
| Monash University researchers studied 2,192 adults and found that every 10 percent increase in ultra-processed food in a person’s diet—about one bag of chips worth—was tied to measurably lower attention and slower mental processing speed. And here’s the part that stung: it didn’t matter how healthy the rest of their diet was. The damage from the processed food was independent. Attention is the gateway to every other thinking skill. When it slips, memory and decision-making follow. |
| Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026 |
|
|
| Your Brain’s Railway Tracks May Hold the Key to Stopping Protein Clumps |
| Baylor College of Medicine found that tubulin—the building block of microtubules, which act like tiny railway tracks inside your neurons—can prevent the toxic protein clumps tied to both Alzheimer’s and Parkinson’s. When tubulin levels are healthy, it steers tau and alpha-synuclein away from forming harmful tangles and puts them back to work doing their normal jobs. When tubulin drops, as it does in Alzheimer’s brains, those proteins go rogue. Boosting tubulin is now a real research target. |
| Nature Communications · March 2026 |
|
|
|
|
| |
| Right now, 158 drugs are being tested across 192 clinical trials for Alzheimer’s—a 40 percent jump over the last decade. The pipeline is the most diverse it has ever been. Three worth watching this week: |
|
| Clears Nearly All Brain Plaque in Six Months—With Far Fewer Side Effects |
| Trontinemab, made by Roche, uses a delivery system called Brainshuttle that hitches a ride on the brain’s own transport system—the transferrin receptor—to get the drug past the blood-brain barrier more efficiently. In early trials, 92 percent of patients tested negative for amyloid plaques after 28 weeks. Brain swelling—a common side effect of current plaque-clearing drugs like lecanemab and donanemab—occurred in less than 5 percent of participants and was mild. Two large Phase 3 trials (TRONTIER 1 and 2) are now enrolling 1,600 people. |
| Phase 3 · Results expected 2028 |
|
|
| Uses Flickering Light and Sound to Slow Brain Shrinkage—No Drugs at All |
| Cognito Therapeutics built a headset called Spectris that delivers pulses of light and sound at 40 hertz—the gamma frequency your brain uses for communication between neurons. In its feasibility trial (OVERTURE), patients using the device kept their thinking and daily function abilities roughly 7 to 10 months longer than those who got a sham device. Their brains also shrank less. A 670-person Phase 3 trial (HOPE) is currently running at over 60 sites across the United States, with results expected in mid-2026. |
| Phase 3 · Results expected mid-2026 |
|
|
| A Pill That Targets Alzheimer’s From Inside the Cell—Not Just the Plaques |
| Blarcamesine, developed by Anavex Life Sciences, works differently from the plaque-clearing antibodies. It activates a receptor called sigma-1, which sits inside brain cells and helps manage protein folding, stress responses, and cellular cleanup. It’s a once-daily pill—no infusions, no injections. A 508-person Phase 2b/3 trial in early Alzheimer’s has been completed, and data analysis is underway. If it works, it would be the first oral disease-modifying treatment for Alzheimer’s. |
| Phase 2b/3 · Data under review |
|
|
